DNA Methyltransferase Inhibitors Improve the Effect of Chemotherapeutic Agents in SW48 and HT-29 Colorectal Cancer Cells
Open accessThe DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
DNA methylation is an epigenetic phenomenon known to play an important role in the development and progression of human cancer. Enzyme responsible for this process is DNA methyltransferase 1 (DNMT1) that maintains an altered methylation pattern by copying it from parent to daughter DNA strands after replication. Aberrant methylation of the promoter regions of genes critical for normal cellular functions is potentially reversible. Therefore, inactivation of DNMT1 seems to be a valuable target for the development of cancer therapies. Currently, the most popular DNMT inhibitors (DNMTi) are cytidine analogues like 5-azacytidine, 5-aza-2'-deoxycytidine (decitabine) and pyrimidin-2-one ribonucleoside (zebularine). In colorectal cancer, epigenetic modifications play an essential role at each step of carcinogenesis. Therefore, we have addressed the hypothesis that DNA methyltransferase inhibitors may potentiate inhibitory effects of classical chemotherapeutic agents, such as oxaliplatin and 5-fluorouracil (5-FU), commonly used in colorectal cancer therapy. Here, our report shows that DNMTi can have positive interactions with standard chemotherapeutics in colorectal cancer treatment. Using pharmacological models for the drug-drug interaction analysis, we have revealed that the combination of decitabine with 5-FU or oxaliplatin shows the most attractive interaction (synergism), whereas the effect of zebularine in combinations with chemotherapeutics is moderate and may be depended on genetic/epigenetic background of a cell line or secondary drug used in combination. Our results suggest that DNMTi administered in combination with standard chemotherapeutics might improve the treatment of patients with colorectal cancers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



![Figure 4 Chemotherapeutic agents, DNMTi and their combinations influence the cell cycle progression of colorectal cancer cells. A. Changes in the cell cycle distribution of SW48 and HT-29 cells after 72 h of treatment with the evaluated agents. The cells were stained with propidium iodide (PI) and then analyzed by flow cytometry. The percentage of cells in each phase of the cell cycle was determined using ModFit LT™ (version 3.0). Each bar represents the mean ±S.D. (n≥4). Significant difference at P<0.05 are indicated by asterisk (*). B. Analysis of CCNE1 and ATM mRNA levels by semi-quantitative RT-PCR method after 72 h incubation of CRC cells with chemotherapeutic agents, DNMTi and their combinations at concentrations as indicated. M, marker [bp]; GAPDH, transcript encoding glyceraldehyde-3-phosphate dehydrogenase, a constitutively expressed gene, used as an internal control. C. Western blotting analysis of the cell cycle regulatory proteins. The β-actin was used as a gel loading control. OXA, oxaliplatin; 5-FU, 5-fluorouracil; DAC, decitabine; ZEB, zebularine.](https://figures.cochat.ai/paper-figures/94c9587eaf914700a5060139a6ad37dc/dna-methyltransferase-inhibitors-improve-the-effect-of-chemotherapeutic-agents-figure-4.jpg)

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For instance, multiple DNMT inhibitors exhibited additive or synergistic effects when combined with 5-FU, oxaliplatin or irinotecan in CRC cell lines [159,160,161].”
From Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer (2025) · cites this paper as [161]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jemal, A., Bray, F., Center, M. M., Ferlay, J., Ward, E., & Forman, D. (2011) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20107 · Cited by 54,679
Chou, T.-C., & Talalay, P. (1984) · Advances in Enzyme Regulation · doi:10.1016/0065-2571(84)90007-4 · Cited by 7,178 · cited 1×
“The nature of the interactions between drugs studied was analyzed with the help of izobologram [11] and combination-index (CI) methods, derived from the median-effect principle of Chou and Talalay [12,13].”
MethodDNA damage-induced cell death: From specific DNA lesions to the DNA damage response and apoptosis
Roos, W. P., & Kaina, B. (2013) · Cancer Letters · doi:10.1016/j.canlet.2012.01.007 · Cited by 879 · cited 1×
“Additionally, we observed a higher level of cyclin A probably connected with down regulation of Cdc25A and elevated phosphorylation of BRCA1 at Ser1524, which is essential for activating the Chk1 kinase and finally G2/M arrest (Figure 3) [34].”
BackgroundAnalysis of combined drug effects: a new look at a very old problem
Chou, T.-C., & Talalay, P. (1983) · Trends in Pharmacological Sciences · doi:10.1016/0165-6147(83)90490-x · Cited by 619
DNA damage-induced activation of ATM and ATM-dependent signaling pathways
Kurz, E. U., & Lees-Miller, S. P. (2004) · DNA Repair · doi:10.1016/j.dnarep.2004.03.029 · Cited by 478
Palii, S. S., Van Emburgh, B. O., Sankpal, U. T., Brown, K. D., & Robertson, K. D. (2008) · Molecular and Cellular Biology · doi:10.1128/mcb.01799-07 · Cited by 382
Preferential response of cancer cells to zebularine
Cheng, J. C., Yoo, C. B., Weisenberger, D. J., Chuang, J., Wozniak, C., Liang, G., Marquez, V. E., Greer, S., Orntoft, T. F., Thykjaer, T., et al. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.06.023 · Cited by 319
DNA methyltransferase inhibitors and their emerging role in epigenetic therapy of cancer.
Gnyszka, A., Jastrzębski, Z., & Flis, S. (2013) · PubMed · Cited by 318
Self-citationFlotho, C., Claus, R., Batz, C., Schneider, M., Sandrock, I., Ihde, S., Plass, C., Niemeyer, C. M., & Lübbert, M. (2009) · Leukemia · doi:10.1038/leu.2008.397 · Cited by 315
The intersection between DNA damage response and cell death pathways.
Nowsheen, S., & Yang, E. S.-H. (2012) · PubMed · Cited by 284
Cited by
Epigenetics of colorectal cancer: biomarker and therapeutic potential
Jung, G., Hernández-Illán, E., Moreira, L., Balaguer, F., & Goel, A. (2020) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0230-y · Cited by 813
KHAN, M. A., HUSSAIN, A., SUNDARAM, M. K., ALALAMI, U., GUNASEKERA, D., RAMESH, L., HAMZA, A., & QURAISHI, U. (2015) · Oncology Reports · doi:10.3892/or.2015.3802 · Cited by 178
Nucleosidic DNA demethylating epigenetic drugs – A comprehensive review from discovery to clinic
Agrawal, K., Das, V., Vyas, P., & Hajdúch, M. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.02.006 · Cited by 135
Norouzi, Z., Salimi, A., Halabian, R., & Fahimi, H. (2018) · Microbial Pathogenesis · doi:10.1016/j.micpath.2018.07.006 · Cited by 126
Vallejo, M. J., Salazar, L., & Grijalva, M. (2017) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2017/4586068 · Cited by 137
Metadata
- Authors
- Flis, S., Gnyszka, A., & Flis, K.
- Affiliations
- Narodowy Instytut Leków (PL)
- Institute of Biochemistry and Biophysics, Polish Academy of Sciences (PL)
- Corresponding author
- Flis, Sylwia
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2014-03-27
- Volume
- 9
- Issue
- 3
- Pages
- e92305
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC3967992
- OpenAlex
- W1966590731
- Cited by
- 53
- References
- 40
- Citations by year
- 2025: 5 · 2024: 4 · 2023: 1 · 2022: 6 · 2021: 2 · 2020: 4 · 2019: 4 · 2018: 5 · 2017: 9 · 2016: 4 · 2015: 6 · 2014: 3
- FWCI
- 3.01
- Type
- journal article
- Language
- en
- Update notices
- correction (2014-08-18)
- Open access
- gold
- doi.org
- Locations
- PLoS ONE (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, other-oa)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Keywords
- hypomethylating agents, colorectal cancer, epigenetic therapy, decitabine, zebularine, azacitidine, oxaliplatin, 5-fluorouracil, drug-drug interactions, synergistic effect, SW48 cells, HT-29 cells, DNA methylation
- MeSH terms
- Oxaliplatin, Decitabine, Antineoplastic Combined Chemotherapy Protocols, Azacitidine, Cell Cycle, Cytidine, DNA Damage, Enzyme Inhibitors, Fluorouracil, Humans, Organoplatinum Compounds, Colorectal Neoplasms, DNA-Cytosine Methylases, Apoptosis, Cell Line, Tumor, Membrane Potential, Mitochondrial
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: DNA Methyltransferase Inhibitors Improve the Effect of Chemotherapeutic Agents in SW48 and HT-29 Colorectal Cancer Cells. https://app.cochat.ai/papers/10.1371/journal.pone.0092305
- The paper
- Flis, S., Gnyszka, A., & Flis, K. (2014). DNA Methyltransferase Inhibitors Improve the Effect of Chemotherapeutic Agents in SW48 and HT-29 Colorectal Cancer Cells. PLoS ONE. https://doi.org/10.1371/journal.pone.0092305
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.